Deubiquitinating enzymes (DUBs) control vital processes in eukaryotes by hydrolyzing ubiquitin adducts. Their activities are tightly regulated, but the mechanisms remain elusive. In particular, the DUB UCH-L5 can be either activated or inhibited by conserved regulatory proteins RPN13 and INO80G, respectively. Here we show how the DEUBAD domain in RPN13 activates UCH-L5 by positioning its C-terminal ULD domain and crossover loop to promote substrate binding and catalysis. The related DEUBAD domain in INO80G inhibits UCH-L5 by exploiting similar structural elements in UCH-L5 to promote a radically different conformation, and employs molecular mimicry to block ubiquitin docking. In this process, large conformational changes create small but highly specific interfaces that mediate activity modulation of UCH-L5 by altering the affinity for substrates. Our results establish how related domains can exploit enzyme conformational plasticity to allosterically regulate DUB activity. These allosteric sites may present novel insights for pharmaceutical intervention in DUB activity.
INTRODUCTION
The ubiquitin conjugation machinery regulates almost every process in the eukaryotic cell. Deubiquitinating enzymes (DUBs) are a critical component of the machinery since they can remove ubiquitin adducts and thereby control the level of ubiquitin signals (Komander et al., 2009) . In accordance with their important roles, DUBs are frequently deregulated in human pathologies including cancer and neurological disease (Clague et al., 2013) , making DUBs potential prime targets for therapeutic intervention.
The level of the intrinsic DUB activity is important and requires precise control. For a subset of DUBs, there is emerging evidence that the catalytic activity can be modulated by regulatory proteins or by internal domains (Sowa et al., 2009 ). Notable examples include USP7 activation by its HUBL domain and GMPS (Faesen et al., 2011) , USP1 activation by UAF1 (Cohn et al., 2007) , and Ubp8 activation in the SAGA complex (Kö hler et al., 2008; Lee et al., 2005) . The most striking example is UCH-L5, for which both activation and inhibition have been observed (Hamazaki et al., 2006; Qiu et al., 2006; Yao et al., 2006 Yao et al., , 2008 by two different proteins, RPN13 (ADRM1) and INO80G (NFRKB), respectively.
Understanding the mechanisms of DUB activation is important for interpreting their roles in specific cellular contexts. Mechanistic insight into regulatory mechanisms also can provide vital information for the development of inhibitors or activators. So far, the only available crystal structure of a DUB-activator complex is that of the SAGA DUB module (Kö hler et al., 2010; Samara et al., 2010) , but no structure is available for its inactive state. Due to this lack of structural data, detailed mechanisms of DUB regulation are still poorly understood.
UCH-L5 (UCH37) is a cysteine protease of the ubiquitin C-terminal hydrolase (UCH) family of DUBs, which also includes UCH-L1, UCH-L3, and BAP1. UCH-L5 is overexpressed in several carcinomas Fang et al., 2012 Fang et al., , 2013 and knockout of the gene is embryonically lethal in mice (Al-Shami et al., 2010) . Functionally, it has been linked to TGF-b signaling, Alzheimer's disease, and longevity (Kikuchi et al., 2013; Matilainen et al., 2013; Wicks et al., 2005 Wicks et al., , 2006 . UCH-L5 constitutes a component of proteasomes and INO80 chromatin remodeling complexes, where it is activated and inhibited, respectively.
As a non-essential component of the proteasome 19S regulatory particle, UCH-L5 catalyzes K48-linked polyubiquitin hydrolysis. This activity requires the RPN13 subunit whose C-terminal domain binds UCH-L5 (Hamazaki et al., 2006; Qiu et al., 2006; Yao et al., 2006) . In vitro, RPN13 is able to directly promote UCH-L5 activity against a minimal substrate (Hamazaki et al., 2006; Qiu et al., 2006; Yao et al., 2006) .
UCH-L5 has a less well-defined role in metazoan INO80 chromatin remodeling complexes. INO80 is an essential determinant of embryonic stem cell identity (Chia et al., 2010; Wang et al., 2014) and participates in the DNA damage response (Smeenk and van Attikum, 2013) , but the function of the metazoan-specific subunits, such as INO80G, is poorly defined. A recent report has implicated UCH-L5 and INO80G as key factors of the DNA double-strand-break response (Nishi et al., 2014) . Interestingly, in the context of the INO80 complex, the DUB activity of UCH-L5 is inhibited by the INO80G subunit (Yao et al., 2008) . Intriguingly, an artificial shorter version of INO80G was found to activate UCH-L5 in vitro (Yao et al., 2008) . The UCH enzymes have a small highly conserved papain-like catalytic domain (CD) characterized by a flexible active site cross-over loop (CL) . The CL is thought to select substrates according to leaving group size (Popp et al., 2009; Zhou et al., 2012) . In UCH-L5 and UCH family member BAP1 the CL is relatively large, enabling them to process larger substrates (Zhou et al., 2012) .
Within the UCH family UCH-L5 and BAP1 are close relatives. BAP1 is a critical tumor suppressor whose regulation is important for proper gene regulation (Carbone et al., 2013; Goldstein, 2011; White and Harper, 2012) . UCH-L5 and BAP1 share an unusual C-terminal helical extension, called ULD (Misaghi et al., 2009) . The ULD domain could mediate protein-protein interactions, including higher-order homo-oligomerization (Burgie et al., 2012; Jiao et al., 2014) , and was proposed to act as an auto-inhibitory module (Yao et al., 2006) .
Like UCH-L5, BAP1 can be activated by a regulatory protein, in this case ASX, to promote H2A deubiquitination (Scheuermann et al., 2010) . Phylogenetic analyses have uncovered a conserved domain within the UCH regulatory proteins RPN13, INO80G, and ASX, which was named the DEUBAD domain (Sanchez-Pulido et al., 2012) . As all three proteins affect UCH activity, it was proposed that the DEUBAD domain is responsible for this modulation. The conservation suggests a common mechanism of regulation, but where ASX and RPN13 activate their cognate DUB, INO80G inhibits it. Thus, the DEUBAD domain has shifted from activator to inhibitor mode. The mechanistic details of this dual mode of action of the DEUBAD domains are unclear.
Here we present structural and functional analyses that explain how DEUBAD domains can switch UCH-L5 activity and thus provide either positive or negative regulation. We show how the DEUBAD domain in RPN13 activates UCH-L5 by tuning the conformation of structural elements in UCH-L5, and inhibits in INO80G, where it exploits molecular mimicry and UCH-L5 conformational plasticity to prevent ubiquitin docking and catalysis. We also show how the inhibitory domain in INO80G has retained the ability to activate, by its N-terminal INO80G short region, and identify the structural elements in the DEUBAD domains that confer the activating or inhibitory effects on UCH-L5 enzymatic activity. Our data show that this remarkable tuning of activity involves large conformational changes and is mediated by precise positioning of both the UCH-L5 C-terminal ULD and active site CL.
RESULTS

Crystal Structures of Activated and Inhibited UCH-L5
To study the regulation of UCH-L5 by DEUBAD domains, we purified human UCH-L5 in complex with the DEUBAD domains of RPN13 (amino acid [aa] 265-388, referred to as RPN13 DEU ) and INO80G (aa 39-170, referred to as INO80G DEU ) ( Figure 1A ).
We measured the catalytic activity of these complexes towards the minimal substrate ubiquitin-7-amido-4-methylcoumarin (Ub-AMC) in comparison to full-length UCH-L5 alone (U) and its isolated CD. In line with previous data, we found that the DEUBAD domain of RPN13 activates UCH-L5 (UR) ( Figure 1B ; Hamazaki et al., 2006; Qiu et al., 2006; Yao et al., 2006) . Since the UCH-L5 CD is more active than the full-length alone, the ULD domain partially inhibits activity (Yao et al., 2006) . However, in the presence of RPN13 DEU , UCH-L5 is significantly more active than the UCH-L5 CD, and, therefore, RPN13 DEU does more than simply remove autoinhibition ( Figure 1B ). Strikingly, INO80G
DEU severely inhibits activity under these conditions (UI) ( Figure 1B ). We wondered how these related DEUBAD domains achieve such remarkably opposite effects on regulation. To assess this, we performed structural studies on UCH-L5 in complex with DEUBAD domains and compared them with apo UCH-L5 (Burgie et al., 2012; Figure 1C ). We determined a crystal structure of UCH-L5 in complex with the inhibitory domain INO80G DEU at 3.7 Å ( Figure 1D ). Additionally, we determined crystal structures of UCH-L5 in complex with activating RPN13 DEU , with and without the suicide inhibitor ubiquitin-propargyl (Ub-Prg) at 2.3 Å and 2.8 Å , respectively ( Figures 1E and 1F ). All structures were refined to acceptable statistics (Table 1) . The resulting structures display striking differences ( Figures  1D-1F ). Both RPN13 DEU and INO80 DEU primarily bind the C-terminal ULD domain of UCH-L5, but are positioned radically differently relative to the UCH-L5 CD, which itself hardly changes conformation among all UCH-L5 structures. The differences arise from major changes in orientation of the ULDs relative to the CD ( Figure 1G ). The ULDs adopt a wide range of positions relative to the CD, even in previously known UCH-L5 structures (Burgie et al., 2012; Maiti et al., 2011; Morrow et al., 2013) , suggesting that this element is flexible in solution. Activator and inhibitor may lock this domain in particular conformations.
To allow UCH-L5 binding, RPN13 DEU changes conformation compared to the previously determined RPN13 DEU apo-state , by rearranging core helices a1-a4 and the Tables 1, S1 , S2, and S4 and Figure S1 .
Molecular Cell 57, 887-900, March 5, 2015 ª2015 The Authors 889 a3-a4 loop ( Figure 1H ). In this new conformation, the cores of INO80G DEU and RPN13 DEU resemble each other, underscoring their common ancestry ( Figures 1I and S1A ). The C termini of the DEUBAD domains, however, diverge dramatically. Where helices a6-a8 (aa 350-384) form a platform in RPN13 DEU , the equivalent region in INO80G DEU forms a single extended helix (a6). Another notable difference between the two DEUBAD domains is a short hairpin (aa 96-103) exclusively present in INO80G, which we named the FRF hairpin. It is inserted between helix a4 and a5 of the DEUBAD domain and is conserved in INO80G orthologs (Figures 1I and S1B) .
The structural conservation of the DEUBAD domains is also reflected in their similar binding modes to UCH-L5 ( Figures 1D-1F and S1C). In both complexes, the core DEUBAD domains bind primarily to the C-terminal ULD of UCH-L5, where amphipathic helix a11 is clasped by the DEUBAD domains and further stabilized by helix a12 in an extensive hydrophobic interface (Figures S1D and S1E). DEUBAD domain binding requires these helices, since a UCH-L5 variant lacking these (UCH-L5 Da11-12 ) does not interact with RPN13 DEU , whereas the wild-type (WT) UCH-L5 binds tightly (K D = 6 nM) in isothermal titration calorimetry (ITC) ( Figure S1F ; Table S4 ). In short, the conserved DEUBAD domains bind to UCH-L5 but show dramatically different arrangements. In the next sections, we examine how these are achieved and how they can lead to differences in UCH-L5 activity. The structural consequences of ubiquitin binding are discussed in light of the mechanism of activation and inhibition.
DEUBAD Domains Tune UCH-L5 Substrate Affinity
Analysis of UCH-L5 kinetic parameters ( Figure 1B ; , which confirmed that DEUBAD domains tune UCH-L5 activity at the level of substrate binding ( Figure 2B ).
Ubiquitin Binding by the UCH-L5/RPN13 DEU Complex UCH-L5 activation by the RPN13 DEUBAD domain results from enhanced ubiquitin-substrate binding; therefore, we analyzed the details of ubiquitin interaction in the UCH-L5UbPrg/ RPN13 DEU crystal structure ( Figure 2C ). The presence of UbPrg hardly changed the global UCH-L5/RPN13 DEU conformation (Figure 1 ). Direct contact between ubiquitin and RPN13 DEU involved a small interface (286 A 2 ) with three hydrogen bonds ( Figures 2C and 2D ). Moreover, this interface did not affect the position and orientation of ubiquitin on UCH-L5, which resembled the previously solved T.spiralis UCH-L5 ubiquitin complex. In fact, it was identical to the canonical ubiquitin-binding mode found in all UCH family members ( Figure 2E ). In practice, ubiquitin binds via its C-terminal tail close to the active site and via its core relatively far from the active site, in a series of so-called exosites. In the UCH-L5 complex, the ubiquitin C-terminal tail adopts an extended conformation. It is buried and positioned by an extensive network of side-chain and backbone interactions with the CD (Figures 2C and 2F ).
The binding of the ubiquitin core creates three specific exosite interactions on the UCH-L5 CD. The first involves UCH-L5 Trp36, which rearranges, compared to apo UCH-L5/RPN13 DEU , to avoid clashes and to promote a direct contact with ubiquitin Ile44 (Figures 2C and 2G ), the primary hydrophobic binding site on ubiquitin. Table S3 and Figure S2B .
A second exosite interaction involves UCH-L5 Ile216 at the C terminus of helix a8 ( Figure 2G ). This helix melts out in UCH-ubiquitin complexes, but is extended in the absence of ubiquitin (Figure S2B ). Partial melting of a8 is crucial since it rearranges Ile216 from a buried position to a position in the a8-b6 connecting loop that is compatible with ubiquitin binding, similar to T.spiralis UCH-L5 where Val214 (equivalent to human Ile216) contacts the ubiquitin Ile36 patch (Morrow et al., 2013;  Figure 2H ). Interestingly, in the UCH-L5/RPN13 DEU structure, the C terminus of helix a8 is already disordered in the absence of ubiquitin, indicating that RPN13 DEU may affect this region allosterically to facilitate ubiquitin binding.
Finally, the melting of helix a8 and ordering of the a8-b6 connecting loop promotes positioning of Phe218 and formation of a highly conserved pocket that includes UCH-L5 Leu38. This hydrophobic pocket on UCH-L5 allows a snug interaction with the ubiquitin b1-b2 hairpin containing Leu8 and Thr9 ( Figure 2G ). Formation of this pocket was described for UCH-L1, upon ubiquitin interaction (Boudreaux et al., 2010) . In UCH-L1 the Phe214 positioning promotes rearrangement of Phe53 (equivalent to UCH-L5 residues, Phe218 and Phe56), which is necessary to organize the catalytic site conformation. In UCH-L5 this relay is not required, since Phe56 is already positioned such that the catalytic triad is active in the apo-structure. Nevertheless, the conformational change of UCH-L5 Phe218 in this pocket is conserved upon ubiquitin binding, as is the interaction with the ubiquitin b1-b2 hairpin. All three exosite interactions are well conserved in the UCH family, explaining the remarkably similar ubiquitin positioning on the UCH CDs ( Figure 2E ).
The DEUBAD Domain of RPN13 Activates UCH-L5 by ULD and CL Positioning To investigate how RPN13 DEU promotes enhanced substrate binding by UCH-L5, we tested the effect of mutations on activity. We first focused on the effect on activation of the ubiquitin-binding residues in UCH-L5. Mutations in these residues lowered the activity substantially, irrespective of the presence of RPN13 DEU , indicating that they are primarily important for basic DUB function ( Figure 3A ). We then tested mutations of RPN13 DEU located in the interface with ubiquitin, and found that these provided only a limited contribution to UCH-L5 activation ( Figures  2D and S2C ).
To further explore the molecular origins of the activation, we analyzed the evolutionary conservation of surface residues on UCH-L5 with ConSurf (Glaser et al., 2003) . A UCH-L5 sequence alignment from species across all major eukaryotic lineages that possess both RPN13 and UCH-L5 was projected onto the UCH-L5 structure. This was compared to an analogous conservation analysis for UCH-L3, a prototype UCH member that lacks the C-terminal ULD domain. We noted several conserved regions. Both UCHs have a conserved surface patch where ubiquitin binds ( Figure 3B ). Adjacent to this patch, we found a second highly conserved site in UCH-L5 orthologs that is absent in UCH-L3 orthologs. This site centers on Glu283 and anchors the ULD to the CD through a polar interaction network (Figure 3C ). The strong conservation of this ULD anchor is intriguing as the area is not directly involved in ubiquitin or RPN13 DEU binding.
We assessed the functional importance of the ULD anchor by testing UCH-L5 mutants in Ub-AMC assays. UCH-L5 E283A had similar activity to WT but this mutant could not be activated to the same extent as WT by RPN13 DEU , mainly due to weaker K M ( Figure 3D ; Tables S1 and S2). The fact that this E283A mutation does not affect intrinsic UCH-L5 activity, but only the activity of the RPN13 DEU complex, strongly suggests that an intact ULD anchor is required for RPN13 DEU -dependent activation of UCH-L5. Next we tested the effect of E283A mutation on substrate binding. Using ITC and stopped-flow binding analysis, we found that UCH-L5 E283A /RPN13 DEU shows decreased affinity for Ub substrates compared to WT complex (Figures S2A and S2D; Table S3 ). This indicates that RPN13 DEU induces a higher affinity for substrates by utilizing the intact ULD anchor. We then focused our attention on the UCH-L5 CL that is disordered in most UCH-L5 crystal structures. In our complexes, the CL makes contacts with RPN13 DEU ( Figure 3E ) via the highly conserved Met148 and Phe149, partially ordering the loop. Given the importance of the CL for the ability of UCHs to process larger substrates (Popp et al., 2009; Zhou et al., 2012) , we made mutants to test whether the interface of the CL with RPN13 DEU could affect activity by positioning the loop. In a Ub-AMC assay, UCH-L5 M148A/F149A hydrolyzed Ub-AMC comparable to WT, indicating that the mutant was still functional. However, this mutant was only marginally activated by the addition of RPN13 DEU (2.7-fold instead of 7-fold in WT), indicating that UCH-L5 activation by RPN13 DEU requires an intact CL ( Figure 3F ; Tables S1 and S2). Interestingly, unlike the ULD anchor mutant, the CL mutant and WT complexes bound model substrates with similar affinities (Figures S2A and S2D ; Table S3 ).
Combining the CL and ULD anchor mutants into UCH-L5 double resulted in an almost complete abrogation of RPN13 DEU -mediated activation, illustrating that the CL and ULD anchor are the principal regulatory sites used by RPN13 DEU ( Figure 3G ). As none of the UCH-L5 mutants were compromised in RPN13 DEU binding, as shown by ITC ( Figure S2E ; Table S4 ), we conclude that RPN13 DEU exerts its stimulatory effect on UCH-L5 through positioning of the CL and ULD anchor.
Mechanism of UCH-L5 Inhibition by INO80G DEU
Our binding assays showed that INO80G
DEU decreases the affinity of UCH-L5 for substrates (Figures 2A and 2B) . To understand this effect, we analyzed how INO80G DEU affects UCH-L5 conformation ( Figure 1 ) in more detail. INO80G DEU alters the ULD domain's relative position and conformation in two specific ways. First, helix a9 and a10 are tilted by 30 compared to the active ULD conformation, and, second, the C-terminal end of helix a10 is bent toward the CD ( Figure 4A ). As a result, sections of the ULD and INO80G
DEU occupy the canonical ubiquitin-binding exosites on UCH-L5 and thus prevent substrate docking ( Figure 4A ). Figures 1D and S1D) . Second, in a neat example of molecular mimicry, the INO80G FRF hairpin binds to the UCH-L5 Leu38 pocket in a fashion that resembles the binding of the structurally analogous ubiquitin b1-b2 hairpin to this pocket ( Figures 4B and 4C) . Next, the C terminus of UCH-L5 helix a8 refolds to make the extra helical turn seen in the apo-structure. As a result, UCH-L5 Ile216 rearranges toward the hydrophobic core, preventing the possibility of the important interaction with the ubiquitin Ile36 patch ( Figure 4D ). Finally, helix a10 bending in the INO80G DEU complex relocates the ULD anchor residues toward UCH-L5 Trp36, creating a novel intramolecular interface consisting of a cation-p stacking interaction between the indole ring of the Trp36 and Arg287 in UCH-L5 helix a10 ( Figure 4E ). This relocation simultaneously precludes Trp36 availability for ubiquitin binding and impedes the formation of the intricate polar interaction network in the ULD anchor that is required for UCH-L5 activation by RPN13 DEU ( Figure 3C (G) Activation of the combined CL and ubiquitin anchor mutants E283A/M148A/F149A is almost completely abrogated compared to WT (UR and U from Figure 1B) . Error bars, SD. See also Figure S2 and Tables S1-S4.
INO80G DEU
Da6 still inhibited UCH-L5 ( Figure 5B ), demonstrating that helix a6 is not required for inhibition under these conditions.
We next assessed the importance of the INO80G FRF hairpin, which is the other major structural difference between the RPN13 DEU and INO80G DEU ( Figures 1I and 5A ). In the hairpin, the side chain of the highly conserved Phe100 ( Figure S1B ) is accommodated by the UCH-L5 Leu38 pocket ( Figure 4C ), suggesting that this interaction is important for INO80G function. To address the relevance of this interaction, we made a singlepoint mutant F100A in INO80G DEU .
This point mutant, INO80G DEU F100A , lost the ability to inhibit UCH-L5 in Ub-AMC assays. In fact, it restored activity to the level of UCH-L5 alone, highlighting the importance of the FRF-hairpin interaction for UCH-L5 inhibition ( Figure 5C ; Tables  S1 and S2 ). Moreover, the F100A complex gained a significant substrate-binding ability in contrast to the WT INO80G DEU complex ( Figure 5D ). Loss of the phenylalanine interaction makes the Leu38 pocket available again for binding of the b1-b2 hairpin of ubiquitin ( Figure 2G ), but most likely also allows helix a10 to revert to its extended state, affecting the ULD position.
The structural changes in the DEUBAD domains may have been a crucial evolutionary event facilitating novel regulatory modes of the DEUBAD domain. To test this we created a chimeric RPN13 DEU variant (RPN13 DEU chimera ) by inserting the INO80G FRF hairpin into the structurally equivalent position in RPN13 DEU ( Figure S3A ). The chimera formed a stable complex with UCH-L5 ( Figure S3B ), but completely abolished the activation effect. The inserted FRF hairpin was not sufficient to inhibit UCH-L5 to the same extent as INO80G DEU however ( Figure 5E ; Table S1 ). In RPN13 DEU chimera the presence of the FRF hairpin likely diminishes ubiquitin binding, as it would be overlapping with the ubiquitin-binding site explaining the loss of activation potential. These results demonstrate that the FRF hairpin and its location within the DEUBAD domain have a crucial effect on UCH-L5 activity. (B and C) The FRF hairpin mimics the ubiquitin b1-b2 hairpin to bind the Leu38 pocket. (D) In contrast to the activated state, helix a8 in UCH-L5 adopts an extended state in the INO80G DEU complex to bury Ile216.
(E) The ULD anchor interaction is disrupted in the INO80G DEU complex due to ULD tilting and helix a10 bending, establishing intramolecular stacking of Arg287 on Trp36.
The INO80G short Activation Mechanism Also Relies on ULD Positioning
We wondered how lack of the FRF hairpin would affect the stucture of UCH-L5 and INO80G. To this end, we determined the 3.7 Å structure of UCH-L5 in complex with Ub-Prg and INO80G short (aa 39-101), a shorter fragment of INO80G DEU (Figure 1A) . The artificial INO80G short construct has the remarkable capability to activate UCH-L5 in vitro (Yao et al., 2008) . INO80G short starts at the same residue as INO80G DEU but terminates in the middle of the FRF hairpin and, hence, is predicted not to contain a folded FRF hairpin. Indeed, in the crystal structure, the C-terminal end of INO80G short could not be unambiguously modeled, indicating that the FRF hairpin is not formed in this complex.
Strikingly, the UCH-L5UbPrg/INO80G short crystal structure resembled the activated RPN13 DEU complex rather than the inhibited state ( Figures 6A, S4A , and S4B). In this complex, the ULD largely reverted to the conformation seen in the activated RPN13 DEU complexes with an extended helix a10 ( Figure S4C ). All conformational changes in UCH-L5 required to create the canonical ubiquitin-binding mode were also in place ( Figures S4D  and S4E ). The structure of INO80G short itself and its binding mode to UCH-L5 were moreover identical to INO80G DEU (apart from FRF hairpin and a5-6) and RPN13 DEU ( Figure S4F ).
Enzyme kinetics analysis confirmed that INO80G short activates UCH-L5 on Ub-AMC ( Figure 6B ). The activation effect correlates with increased affinity for substrates, since UCH-L5 binds substrates better in the presence of INO80G short in ITC-binding assays ( Figure 6C ). These results stress that DEUBAD domains mainly modulate activity by tuning substrate affinity.
The similarity in structure to the RPN13 DEU complex suggests that INO80G short makes use of the same activation mechanism.
To test this hypothesis, we used the UCH-L5 E283A ULD anchor mutant, asking whether loss of the ULD anchor would also affect the activation in this case. We found that the UCH-L5 E283A / INO80G short mutant complex was compromised in Ub-AMC hydrolysis ( Figure 6B ; Tables S1 and S2), reverting to the activity observed for UCH-L5 alone. This finding indicates the importance of the ULD anchor ( Figure 6D ) for INO80G short activation, and it suggests that ULD positioning in general is a major feature of the activation. INO80G short , containing only the helices a2-a4 of the DEUBAD domain, can activate UCH-L5, demonstrating that the core DEUBAD fold is already sufficient to bind and provide modest activation. The INO80G short complex does not attain UCH-L5/RPN13 DEU activity levels however. Most likely this is because it lacks helix a5, which RPN13 DEU uses to position the CL ( Figure S4G) . Collectively, the UCH-L5/INO80G short structure analysis reconciled all our previous findings. First, it confirmed that the FRF hairpin is the crucial factor for inhibition, since absence of this element resulted in loss of inhibition. Second, loss of the FRF hairpin destabilized the inhibitory ULD conformation, causing it to snap back to a substrate-binding-competent conformation. Third, the core DEUBAD fold was sufficient to provide the basic UCH-L5 activation function. Like RPN13 it executed activation by stabilizing the substrate-binding-competent conformation of the ULD through the ULD anchor.
DISCUSSION
Our data show how UCH-L5 activity can be modulated by DEUBAD domains present in RPN13 and INO80G through remarkably large conformational changes. Functionally, the activity of UCH-L5 is tuned at the level of substrate affinities, where Figure 1F ), but not the UCH-L5/ INO80G DEU structure (right from Figure 1D ).
(legend continued on next page) A key feature of UCH-L5 activity modulation is the conformational plasticity of the ULD that is found in a variety of conformations in the available UCH-L5 crystal structures ( Figure 1G ). This plasticity and the current data are consistent with a model where the UCH-L5 ULD can adopt a multitude of possible conformations in a dynamic fashion when free in solution (Figure 6E) . As a consequence of the ULD's proximity to the ubiquitin docking site, some of these conformations are sterically incompatible with ubiquitin binding while others allow efficient ubiquitin binding. The DEUBAD domain in RPN13 DEU and INO80G DEU restricts ULD conformational plasticity by preferentially stabilizing specific conformations. RPN13 DEU activates and increases the affinity for substrates by fixing the ULD into a substrate-binding-competent conformation, using the ULD anchor. Additionally, full activation is achieved by the stabilization of the ubiquitin orientation by RPN13 DEU and correct positioning of the CL. On the other hand, INO80G DEU binds to UCH-L5 and uses ULD conformational flexibility to dock its unique inhibitory FRF hairpin into the Leu38 pocket. This interaction fixes the ULD in such a way that the ubiquitin-binding site is blocked by INO80G DEU and the ULD. In the process, key molecular elements for ubiquitin binding and RPN13-dependent activation are masked or disrupted, effectively inhibiting activity. This regulatory model may co-exist with possible roles of the UCH-L5 oligomeric state for regulation of its activity (Burgie et al., 2012; Jiao et al., 2014; Yao et al., 2006) . As the enzyme concentrations under our assay conditions were low, it is unlikely that we captured these phenomena. However, we cannot exclude that additional layers of regulatory complexity may exist in cells that involve UCH-L5 oligomeric states.
Our structures of UCH-L5/RPN13 DEU explain the basic mechanisms of activation by the RPN13 DEUBAD module. It will be interesting to investigate the additional activation that is required to hydrolyze K48-polyubiquitin in the proteasomal 19S regulatory particle. It is conceivable that efficient K48-polyubiquitin hydrolysis will only take place after steps that are possibly related to proper positioning and unfolding of the compact K48-polyubiquitin chains. A key step here will be the identification of the minimal proteasomal complex required to perform chain hydrolysis. The UCH-L5/INO80G DEU structure may provide novel approaches in unraveling the enigmatic role of UCH-L5 and INO80G in INO80 chromatin-remodeling complexes. INO80G is a key factor in embryonic stem cells and knock out leads to loss of pluripotency (Wang et al., 2014) . Of specific interest is why UCH-L5 is kept in an inhibited state in the INO80 complex (Yao et al., 2008) . A possibility is that INO80 controls UCH-L5 in a temporal manner, where in some circumstances UCH-L5 is inhibited while under other circumstances post-translational modifications (PTMs) and/or conformational changes release the inhibition and activate UCH-L5, allowing for additional layers of regulation. We have already seen in INO80G short that the core DEUBAD fold has the intrinsic ability to activate UCH-L5 and all that is required for INO80G DEU to relieve inhibition is disruption of the FRF hairpin. Such relief of inhibition would be important for the recently reported UCH-L5/INO80G role in DNA doublestrand-break response, since UCH-L5 catalytic activity is required for proper DNA end resection (Nishi et al., 2014) . A unique element of the INO80G DEU domain is the extended helix a6. This helix packs against the CD close to the active site and, therefore, initially was thought by us to confer INO80G DEU inhibitory function. In our in vitro assays, this element was dispensable for inhibition, but this may be different in a cellular context where the additional contacts between this helix and the CD may further stabilize the inactivated state. An interesting feature of helix a6 is the presence of a large solventexposed positively charged patch. We speculate that this patch may be important in cells as a binding platform for INO80 chromatin-remodeling factors. As the equivalent region in RPN13 DEU folds into a helical platform, it also may be possible that, under some conditions, driven by PTMs for example, a6 could refold into a conformation seen in RPN13 to meet functional requirements. DUB activity regulation by PTMs such as phosphorylation have been shown previously to be important for DUBA (Huang et al., 2012) . The ULD is conserved in UCH family member BAP1 that is activated by the ASXL1 DEUBAD domain to deubiquitinate H2A (Scheuermann et al., 2010) . Because of the strong conservation of key elements between UCH-L5/RPN13 DEU and (B) INO80G short (UI short ) can activate UCH-L5, albeit not to RPN13 DEU levels (UR, UI, and U from Figure 1B) , and depends on the ULD anchor for activation on Ub- Figure 3A) . Figure S4 and Tables S1-S3.
AMC. Error bars, SD. (C) Activation by INO80G short correlates with enhanced Ub-GlySerThr binding in ITC compared to WT UCH-L5 (from
Molecular Cell 57, 887-900, March 5, 2015 ª2015 The Authors 897 BAP1/ASXL1, we anticipate that the ASXL1 DEUBAD domain employs similar strategies to activate BAP1. Both BAP1 and ASXL1 are important cancer drivers. BAP1 is a key tumor suppressor that is mutated in a number of cancers where loss of BAP1 is associated with poor prognosis and tumor aggressiveness (Carbone et al., 2013; White and Harper, 2012) . Our crystal structures have valuable implications for BAP1 function in its cellular roles and pathogenesis. The mechanisms of DUB regulation that we have described are different from those in previously studied DUB regulators. UAF1 increases the basicity of the USP1 catalytic histidine, increasing its potency as a general base (Villamil et al., 2012) . Likewise, incorporation of Ubp8 in the SAGA complex stabilizes the catalytic center, also facilitating catalysis (Kö hler et al., 2010; Samara et al., 2010) . Activation of USP7 by GMPS against a minimal substrate changes only k cat (Faesen et al., 2011) . All of these differ from UCH-L5 where a major part of the activity modulation involves tuning substrate affinities, rather than actual catalytic steps.
Whereas inhibition of DUBs by proteins is still a rare phenomenon, inhibition of general proteases by proteins has been well described (Dubin, 2005; Rzychon et al., 2004) . Serpins inhibit serine proteases by irreversibly trapping the acyl-enzyme intermediate. Additionally, general cysteine proteases can be inhibited by cystatins and related proteins by occupying active site clefts. Instead, INO80G functions as an exosite inhibitor where not the active site cleft but an exosite, in this case the ubiquitin-core-docking site, is blocked. Enzyme exosite targeting by a naturally evolved inhibitor could provide powerful clues about the most efficient way for DUB inhibition, and may thus be promising from a pharmaceutical perspective.
EXPERIMENTAL PROCEDURES Plasmids and Cloning
Human UCH-L5, RPN13, and INO80G cDNA were subcloned from the HAP1 cell line. RPN13 DEU chimera was purchased as a synthetic construct. All constructs were cloned into the pGEX or pET bacterial expression vectors of the NKI LIC suite .
Protein Expression and Purification
All protein variants and protein complexes were (co-) expressed in E.coli. UCH-L5 and variants were purified using glutathione S-transferase (GST) affinity purification (GSH 4B sepharose, GE Healthcare) followed by a desalting (HiPrep 26/10, GE Healthcare) and final size-exlusion chromatography step (Superdex S200, GE Healthcare). UCH-L5 complexes were purified similarly except for an additional first nickel purification step. RPN13 DEU alone was expressed in E.coli and purified using nickel affinity chromatography, desalting, and size-exclusion chromatography (Superdex S75, GE Healthcare).
Ub-AMC Enzymatic Assays
Enzyme activity was followed as release of fluorescent AMC from the quenched Ub-AMC substrate, providing a direct readout of DUB activity. MichealisMenten parameters were determined using 1 nM enzyme while varying the substrate concentration. Initial rates were plotted against substrate concentration and fitted to the Michealis-Menten model using non-linear regression in Prism 6. In single-concentration experiments, 1 nM enzyme was allowed to react with 1 mM substrate. Activity was quantified by calculating the initial rates. 
FP Binding Assays
Structure Determination
Data collection was done at the European Synchrotron Radiation Facility and Swiss Light Source at 100K. Images were integrated with XDS and merged/scaled with Aimless , followed by molecular replacement with Phaser ). Model refinement was carried out by Phenix , autoBUSTER (Smart et al., 2012) , and Refmac , and models were built using COOT . All structure figures were generated using PyMOL. DEU complex. The ULD is clasped by the INO80G DEUBAD domain in an hydrophobic interface (1). Helix α6 packs against the UCH-L5 catalytic domain (2 and 3). E. Close up of the main interface between RPN13 DEU and UCH-L5. F. UCH-L5 helices α11-α12 are required to bind RPN13 DEU in ITC binding assays. In UCHs in complex with ubiquitin (pdb codes: 1ucha, 1xd3, 2etl, 2wdt, 2we6, 3irt, 3kvf, 3kw5, 4dm9, 4i6n, 4ig7, 4jkj , UR, URUB shown in blue/green tints.) helix 8 is partially melted at the C-terminus. This is in contrast with apo UCH structures (pdb codes: 1cmx, 2len, 3a7s, 3ihr, 3rii, 3ris, 3tb3 shown in gray tints.) were helix 8 makes an extra turn C. RPN13 DEU mutants in the ubiquitin interface have a small effect on UCH-L5 activation. "U" from Figure 1B A. Asymmetric unit of UCH-L5~Ub-Prg/INO80G short shows 4-fold non-crystallographic symmetry. B. Superposition of the UCH-L5~Ub-Prg/INO80G short (UCH-L5 in blue) and UCH-L5~Ub-Prg/RPN13 DEU (UCH-L5 in gray) shows that the complexes look similar. C. The ULD of the INO80G short complex (lightblue) has reverted from the inhibited orientation (darkgrey) to a orientation similar to the RPN13 DEU complex (lightgray) D and E. Ubiquitin binding occurs in canonical fashion in the INO80G short complex. F. The DEUBAD domain of INO80G short and its binding mode to UCH-L5 are highly similar to the RPN13 DEU and INO80G DEU complexes. G. INO80G short lacks helix α5 that RPN13 DEU employs to bind and position the UCH-L5 CL. 
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Supplemental experimental procedures Plasmids and cloning
Human UCH-L5 (uniprot Q9Y5K5, isoform3) RPN13 (uniprot Q16186), INO80G (uniprot Q6P4R8) were produced from a cDNA library originating from HAP1 cells (Carette et al., 2011) (aa 39-101) into pETNKI-his3C-LIC (kanamycin), Point mutations were generated using site directed mutagenesis procedure by Quikchange (Agilent). Ub-GlySerThr was produced from WT ubiquitin (pET 3A) via Quikchange insertional mutagenesis. DNA for RPN13 DEU chimera was purchased commercially as a codon optimized gene ( Figure S3A ) and cloned into pETNKI-his3C-LIC (kanamycin). All clones were verified using DNA sequencing.
Protein expression and purification
All proteins were expressed in BL21 Rosetta2 T1-resistent competent cells (Novagen). Cells were grown at 37˚C to an OD 600 of ~0.6 before inducing protein expression by the addition of 0.25 mM IPTG. Expression took place for 4-6 hours at 25˚C after which cells were harvested. UCH-L5 complexes, UCH-L5 complexes UCH-L5/RPN13 DEU , UCH-L5/INO80G DEU , UCH-L5/INO80G short and their mutants were co-expressed.
All purification steps were performed in the cold room or on ice. Cells were lysed by sonication in lysis buffer (50 mM Tris-HCl pH 8.0, 200 mM NaCl, 50 mM Imidazole and 0.5 mM TCEP) in the presence of complete EDTA-free protease inhibitor cocktail (Roche). GST-tagged UCH-L5 variants were purified by GST affinity chromatography using GSH 4B sepharose beads (GE Healthcare) and eluted with 25 mM Tris-HCl pH 8.0, 150 mM NaCl, 50 mM GSH reduced pH 8.0, 10% glycerol, 0.5 mM TCEP after first washing beads with >10 column volumes (CV) lysis buffer. Excess of DNA was removed by
ResourceQ anion exchange chromatography (GE Healthcare) using a linear gradient from 0-75% buffer B (25 mM Tris-HCl pH 8.0, 1000 mM NaCl, 0.5 mM TCEP). The column was equilibrated with Buffer A (25 mM Tris-HCl pH 8.0, 50 mM NaCl, 0.5 mM TCEP).
In case of the UCH-L5 complexes, first nickel affinity chromatography was performed using chelating sepharose (GE Healthcare) pre-loaded with Ni 2+ to pull down either His-RPN13 DEU , His-INO80G DEU or
His-INO80G short . Protein was eluted using 25 mM Tris-HCl pH 8.0, 200 mM NaCl, 250 mM Imidazole pH 8.0, 10%gly and 0.5 mM TCEP before applying the resulting eluate to GST affinity chromatography (see above). His tagged RPN13 DEU alone was purified by nickel affinity chromatography as described above. INO80G DEU or its variants were unstable/insoluble and were therefore not purified as single proteins.
After the initial affinity or anion exchange chromatography steps samples all single variants proteins and complexes were desalted against desalting buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 10% glycerol, 0.5 mM TCEP) using a 26/10 desalting column (GE Healthcare). For GST-fusion proteins, this was followed by o/n cleavage with GST-3C-protease in the cold room. A GlyProGly tripeptide remained at the protein N-terminus after 3C cleavage. GST and GST-3C-protease were removed by reverse purification using GSH beads (GE Healtcare). Samples were next concentrated with Amicon Ultra 15 concentrating columns (Millipore) and injected onto a Superdex S200 or S75 size exclusion chromatography column (GE Healthcare) in gel filtration buffer (10 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP). Positive fractions were concentrated to 3-15 mg/ml, aliqotted and flash frozen in liquid nitrogen to be stored at -80˚C.
Preparation of Ub-Propargyl complexes
Ubiquitin-propargyl (UbPrg) is a suicide inhibitor ) that reacts selectively with the DUB active site cysteine creating an irreversible quarternary vinyl thioether bond, that serves as transition states mimic. UbPrg was synthesized and purified as described . Typically 10-40 µM of either UCH-L5/RPN13 DEU or UCH-L5/INO80G short was reacted with a 2-fold molar excess of UbPrg. The reaction took place in desalting buffer supplemented with 5 mM DTT and was allowed to proceed for 3h on ice or o/n. The reaction mixture was subsequently fractionated on a Superdex S200 size exclusion chromatography column (GE Healthcare) in gel filtration buffer after which the positive fractions were concentrated to ~10 mg/ml and used in crystallization trials.
Ub-AMC enzymatic assays
Enzyme activity was followed as release of fluorescent AMC from the quenched Ub-AMC substrate, providing a direct read-out of DUB activity . Ub-AMC was synthesized as described previously . The purified Ub-AMC was dissolved in pure DMSO. The residual amount of DMSO left in the enzymatic reaction was never higher than 6%. Kinetic parameters were determined using 1 nM of enzyme while varying the substrate concentration in 30µl reactions using reaction buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 5 mM DTT and 0.05% Tween-20) at 25˚C.
Reactions took place in black 384-well non-binding surface low flange plates (Corning). In the single concentration experiments, 1 nM of enzyme was allowed to react with 1 µM of substrate and activity was quantified by calculating the initial rates. Experiments were performed in a Pherastar (BMG Labtechnologies) plate reader using 350 nm and 450 nm excitation and emission wavelengths respectively. Measurements were taken every 10 s for 10 minutes. Fluorescence and velocities were related using an AMC standard curve. The initial rates were plotted against substrate concentration and fitted to the Michealis-Menten model using non-linear regression in Prism 6. Error bars represent the standard deviation. At least 2 different preparations were measured in duplicate per enzyme/complex variant.
Equilibrium FP binding assays
Binding assays between UCH-L5 complexes and model substrate Ub-LysGly TAMRA were performed by measuring fluorescence polarization at room temperature. In this substrate a TAMRA-labeled Lys-Gly dipeptide is conjugated to ubiquitin via an isopeptide bond. To prevent hydrolysis of the substrate in these assays, the active site cysteine of UCH-L5 was mutated to alanine (C88A). Assays were carried out using 10 nM model substrate Ub-LysGly TAMRA with varying concentrations of UCH-L5 variants at 25˚C in FP binding buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 0.05% Tween-20, 1mg/ml BSA, 0.5 mM TCEP). Reactions were 10-20 ul volumes and were allowed to equilibrate before measuring FP in a Pherastar (BMG Labtechnologies) with an excitation filter of 531 nm, and P and S emission filters of 579 nm. Error bars represent the standard deviation. 
Isothermal titration calorimetry
To determine the affinities between UCH-L5 variants and RPN13 DEU and UCH-L5 complexes to model substrate UbGlySerThr ITC experiments were performed. In UbGlySerThr, ubiquitin Gly76 is fused via a peptide bond to the tri peptide GlySerThr. Measurements were done in a VP-ITC Microcal calorimeter at 25˚C in binding buffer (25 mM HEPES pH7.5, 150 mM NaCl, 10% Glycerol and 0.5 mM TCEP). Prior to the experiment both binding partners were dialyzed separately in the same container to equilibrate buffers. The syringe contained 450 µM UbGlySerThr while 45 µM of UCH-L5 variant was present in the cell. For the UCH-L5/RPN13 binding, 110 µM UCH-L5 was present in the syringe. Ten µl of sample was added to the cell per injection. Data were fitted to a one-site binding model with the manufacturer's Origin software. Experiments not showing saturation were not fitted.
Due to lack of absorbance at 280 nm and weak Coomassie staining, RPN13 DEU concentrations were difficult to estimate. Therefore a 1:1 stoichiometry of UCH-L5 and RPN13 DEU was assumed during curve fitting, in line with the crystal structures. In this way, the concentration of RPN13 DEU in the cell was calculated to be 12.5 µM.
Structure determination
The complexes were crystallized using the vapor diffusion method in sitting drops. X-Ray data collection was done at the European Synchrotron Radiation Facility (ESRF) and Swiss Light Source (SLS) at 100K. The images were integrated with XDS or iMosflm (Battye et al., 2011) and merging/scaling was performed in Aimless .
In all cases starting phases were obtained by molecular replacement (MR) in Phaser ). Model refinement was carried out in Phenix , autoBUSTER (Smart et al., 2012) and Refmac with TLS. Models were build using COOT . Data collection and refinement results are presented in table 1.
UCH-L5/RPN13
DEU was crystallized at 4˚C in 100 mM Bis-Tris-Propane pH 6.4, 230 mM NaBr, 21%PEG 3350. Data was collected at ESRF ID14-4. UCH-L5 (3ihr) was used as a MR search model.
Initial MR with apo RPN13 failed due to the large conformational changes in complexed RPN13 DEU .
Initial electron density maps showed density for RPN13 DEU helix α5. After iterative cycles of manual building of RPN13 DEU refinement in refmac and autoBUSTER, most of the RPN13 DEU backbone and side chains could be discerned. To confidently build RPN13 DEU helices 1 and 2, the UCHL5~UbPrg/RPN13 DEU structure that was obtained later at higher resolution was used. Of the 328 residues in full length UCH-L5, 7-150, 163-244 and 254-315 were build into density. Of the RPN13 DEU construct (aa 265-388), residues 287-384 were modeled.
To determine the structure of the UCH-L5~UbPrg/RPN13 DEU complex, we crystallized the complex at 4˚C in 100 mM Bis-Tris-Propane pH 5.8, 300 mM NaBr, 21%PEG 3350 and measured diffraction at ESRF ID23-2. MR was performed using the partially build UCH-L5/RPN13 DEU structure. After obtaining a solution, ubiquitin could be unambiguously docked into the difference density. Cycles of building and refinement with Refmac allowed completion RPN13 DEU model, where residues 287-384 could be modeled (of 265-388). UCH-L5 residues, 6-153, 160-245 and 253-320 were build into density. All residues of ubiquitin were build.
The inhibitory UCH-L5/INO80G DEU was crystallized at room temperature in 100 mM Tris pH 9.0, 200 mM LiCl, 17% PEG 8000. Two isomorphous datasets were collected on ID23-2 at the ESRF, and PXIII at the SLS, that were merged. structures. NCS restraints were employed during refinement as well as high-resolution target restraints. UCH-L5 and ubiquitin from the 2.3 Å UCH-L5~UbPrg/RPN13 DEU structure were used a target in autoBUSTER and phenix.refine.
Structure improvement and validation were performed by PBD_redo and Molprobity Joosten et al., 2014) .
Structure and sequence alignments
Visual analysis of our UCH-L5 structures indicated that the ULD is the main conformationally flexible region. Pairwise structural superpositions of our complexes with RAPIDO (Mosca et al., 2008) confirmed this and identified the UCH-L5 catalytic domain (aa 1-226) as common invariant region. All subsequent structural alignments of UCH-L5 complexes were subsequently performed using aa 1-226 in SSM to allow for multiple structural alignments. Structural superpositioning of the DEUBAD domains was performed by SSM, using the pdbeFold webserver (Krissinel and Henrick, 2005) .
Other multiple sequence alignment were generated using the MAFFT algorithm (Katoh and Toh, 2008) . Sequence alignment figures were generated with Jalview (Waterhouse et al., 2009 ).
